TWI880995B - 急性骨髓性白血病或骨髓發育不良症候群的治療 - Google Patents
急性骨髓性白血病或骨髓發育不良症候群的治療 Download PDFInfo
- Publication number
- TWI880995B TWI880995B TW109142965A TW109142965A TWI880995B TW I880995 B TWI880995 B TW I880995B TW 109142965 A TW109142965 A TW 109142965A TW 109142965 A TW109142965 A TW 109142965A TW I880995 B TWI880995 B TW I880995B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- dose
- days
- myeloid leukemia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| US62/944,876 | 2019-12-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202134237A TW202134237A (zh) | 2021-09-16 |
| TWI880995B true TWI880995B (zh) | 2025-04-21 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109142965A TWI880995B (zh) | 2019-12-06 | 2020-12-04 | 急性骨髓性白血病或骨髓發育不良症候群的治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12533357B2 (https=) |
| EP (1) | EP4069246A4 (https=) |
| JP (1) | JP2023505301A (https=) |
| KR (1) | KR20220124177A (https=) |
| CN (1) | CN115397429A (https=) |
| AU (1) | AU2020396807A1 (https=) |
| BR (1) | BR112022011052A2 (https=) |
| CA (1) | CA3163796A1 (https=) |
| IL (1) | IL293623A (https=) |
| MX (1) | MX2022006910A (https=) |
| TW (1) | TWI880995B (https=) |
| WO (1) | WO2021108918A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| JP7717842B2 (ja) | 2021-05-11 | 2025-08-04 | オリック ファーマシューティカルズ，インク． | ポロ様キナーゼ４阻害剤 |
| US20250049787A1 (en) * | 2021-12-22 | 2025-02-13 | University Health Network | Treatment for acute myeloid leukemia or lymphoma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046949A1 (en) * | 2017-09-08 | 2019-03-14 | University Health Network | POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2465971T3 (es) | 2009-04-06 | 2014-06-09 | University Health Network | Inhibidores de quinasa y método para tratar cáncer con los mismos |
| SI2556071T1 (sl) * | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| ES2706066T3 (es) * | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| WO2015051304A1 (en) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in treatment of cancer |
| HUE043194T2 (hu) * | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| JP6617208B2 (ja) | 2017-03-31 | 2019-12-11 | ノバルティス アーゲー | 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン |
| EP3720560A4 (en) * | 2017-12-06 | 2022-01-05 | Ludwig Institute for Cancer Research Ltd | METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS |
-
2020
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 US US17/782,632 patent/US12533357B2/en active Active
- 2020-12-04 AU AU2020396807A patent/AU2020396807A1/en active Pending
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko active Pending
- 2020-12-04 TW TW109142965A patent/TWI880995B/zh active
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/en active Pending
- 2020-12-04 CA CA3163796A patent/CA3163796A1/en active Pending
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/en not_active Ceased
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046949A1 (en) * | 2017-09-08 | 2019-03-14 | University Health Network | POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE |
Non-Patent Citations (2)
| Title |
|---|
| 期刊 Zhao Y, et al. "Targeting polo-like kinase 4 for therapeutic benefit in the patients with diffuse large B-cell lymphoma" Blood 134(suppl 1): 2019/11/13; 2568 |
| 網路文獻 University Health Network, NCT03187288 "Study of CFI-400945 fumarate in patients with relapsed or refractory AML of MDS", ClinicalTrials.gov. version date:2018/8/13 https://clinicaltrials.gov/study/NCT03187288?tab=history&a=5#version-content-panel;期刊 Zhao Y, et al. "Targeting polo-like kinase 4 for therapeutic benefit in the patients with diffuse large B-cell lymphoma" Blood 134(suppl 1): 2019/11/13; 2568 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115397429A (zh) | 2022-11-25 |
| US12533357B2 (en) | 2026-01-27 |
| WO2021108918A1 (en) | 2021-06-10 |
| AU2020396807A1 (en) | 2022-07-21 |
| CA3163796A1 (en) | 2021-06-10 |
| MX2022006910A (es) | 2022-11-09 |
| KR20220124177A (ko) | 2022-09-13 |
| BR112022011052A2 (pt) | 2022-08-16 |
| EP4069246A4 (en) | 2023-12-06 |
| EP4069246A1 (en) | 2022-10-12 |
| TW202134237A (zh) | 2021-09-16 |
| JP2023505301A (ja) | 2023-02-08 |
| IL293623A (en) | 2022-08-01 |
| US20230010772A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI880995B (zh) | 急性骨髓性白血病或骨髓發育不良症候群的治療 | |
| AU2012321110A1 (en) | Combination treatment | |
| JP7266030B2 (ja) | リンパ球悪性疾患を治療するための方法 | |
| JP2017522281A (ja) | キノリン誘導体による軟部組織肉腫の治療方法と用途、及び軟部組織肉腫治療するための薬用組成物 | |
| WO2013184621A1 (en) | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease | |
| US12440495B2 (en) | Combination therapy for treatment of myeloproliferative neoplasms | |
| IL298200A (en) | Combination therapy for treatment of myeloproliferative neoplasms | |
| US20230132982A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| TWI849001B (zh) | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| US20250049787A1 (en) | Treatment for acute myeloid leukemia or lymphoma | |
| EA049792B1 (ru) | Лечение острого миелоидного лейкоза или миелодиспластического синдрома | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN121969369A (zh) | Parp-1选择性抑制剂和替莫唑胺的组合及其治疗神经胶质瘤的用途 | |
| EP4444303A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
| AU2014264318B2 (en) | Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck |